title: Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients.
abstract: BACKGROUND
  Rapid cycling (RC) in bipolar disorders is widely believed to predict future morbidity and poor treatment response, although empirical testing of its predictive utility remains limited.
  
  
  METHODS
  In 360 DSM-IV bipolar I (N=218) and II (N=142) disorder subjects (64% women) followed over an average of 13.3 years, we evaluated factors associated with RC status with bivariate and multivariate techniques, and response to lithium maintenance treatment (recurrence rates, time ill, survival analysis of time to recurrence on lithium).
  
  
  RESULTS
  RC risk (15.6% of cases) was 5. 1-times greater in bipolar II vs. I subjects (30.3%/6.0%), in minor excess in women vs. men (17.9%/11.5%), and associated with premorbid cyclothymia, depressive first episodes, older onset age, and being employed or married. Before lithium, RC vs. non-RC cases had more mean total (3.9/1.2), manic, and depressive episodes/year, and greater percent time ill (60%/38%). During treatment, prior RC status was unrelated to time to first recurrence and other measures of morbidity and improvement including percent time ill, although depressive episodes were 2.7-times more frequent, and there was 13.7% less chance of full protection from all recurrences in RC cases.
  
  
  CONCLUSIONS
  The study is naturalistic, without random assignment or blind assessment.
  
  
  CONCLUSIONS
  The RC bipolar subtype was strongly associated with type II diagnosis, higher average prelithium episode frequency and percent time ill, and weakly with female sex, but not with greater overall morbidity during treatment.
authors: International Consortium for Bipolar Disorder Research, MA, Boston, USA. rjb@mclean.org
authors: R J
authors: RJ
authors: Baldessarini
authors: L
authors: L
authors: Tondo
authors: G
authors: G
authors: Floris
authors: J
authors: J
authors: Hennen
mesh_terms: D018692:Antimanic Agents / Q000097:blood / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D016651:Lithium Carbonate / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D010507:Periodicity; D011237:Predictive Value of Tests; D015995:Prevalence; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index
chemical_list: D018692:Antimanic Agents; D016651:Lithium Carbonate